Patient quality of life · Patients with cancer receiving chemotherapy and/or radiotherapy with overt oral candidiasis
The review found no eligible studies for this question.
1 finding from 1 review
None of the studies reported: relief of pain, relief of dysphagia, incidence of systemic infection, amount of analgesia, days stay in hospital, cost of oral care, patient quality of life.
0 studies
No studies found
Time to heal mucositis (days) · People with cancer receiving chemotherapy or radiotherapy (or both) who have oral mucositis
Allopurinol mouthwash led to lower time to heal mucositis (days) compared with placebo; GRADE not reported.
1 finding from 1 review
Improvement in mucositis · People with cancer receiving chemotherapy or radiotherapy (or both) who have oral mucositis
Polyvariant intramuscular immunoglobulin led to higher improvement in mucositis compared with placebo; GRADE not reported.
1 finding from 1 review
Time to complete healing · Patients being treated for cancer with established oral HSV infection (bone marrow transplant recipients / immunocompromised)
1 finding from 1 review
Two studies. Median time to total healing was shorter for patients receiving oral or intravenous aciclovir than placebo: median of 8 days versus 21 days, P = 0.01 (Shepp 1985); 13.9 days versus 20.7 days, P = 0.08…
2 studies
GRADE not reported
Amount of analgesia · Patients being treated for cancer (predominantly haematological malignancies)
The review found no eligible studies for this question.
1 finding from 1 review
None of the prophylactic aciclovir versus placebo trials reported on amount of analgesia. For prevention or treatment, no trials reported on duration of hospital stay, amount of analgesia or patient quality of life.
0 studies
No studies found
Recurrence of lesions · Patients being treated for cancer with established oral HSV infection (bone marrow transplant recipients / immunocompromised)
The review found no eligible studies for this question.
1 finding from 1 review
For the treatment comparison (aciclovir versus placebo), no data were available for recurrence of lesions, amount of analgesia, days of stay in hospital, cost of oral care or patient quality of life.
0 studies
No studies found
Duration of viral shedding · Patients being treated for cancer with established oral HSV infection (bone marrow transplant recipients / immunocompromised)
1 finding from 1 review
Patient quality of life · Patients being treated for cancer (predominantly haematological malignancies)
The review found no eligible studies for this question.
1 finding from 1 review
None of the prophylactic aciclovir versus placebo trials reported on patient quality of life. For prevention or treatment, no trials reported on duration of hospital stay, amount of analgesia or patient quality of life.
0 studies
No studies found
Relief of pain · Patients being treated for cancer with established oral HSV infection (bone marrow transplant recipients / immunocompromised)
1 finding from 1 review
Length of hospital stay · Patients being treated for cancer with established oral HSV infection (bone marrow transplant recipients / immunocompromised)
The review found no eligible studies for this question.
1 finding from 1 review
For the treatment comparison (aciclovir versus placebo), no data were available for recurrence of lesions, amount of analgesia, days of stay in hospital, cost of oral care or patient quality of life.
0 studies
No studies found
Viral isolates (HSV isolates identified, with or without clinical symptoms) · Patients being treated for cancer (predominantly haematological malignancies)
Prophylactic aciclovir (oral or intravenous) led to lower viral isolates (HSV isolates identified, with or without clinical… compared with placebo; GRADE not reported.
1 finding from 1 review
Amount of analgesia · Patients being treated for cancer with established oral HSV infection (bone marrow transplant recipients / immunocompromised)
The review found no eligible studies for this question.
1 finding from 1 review
For the treatment comparison (aciclovir versus placebo), no data were available for recurrence of lesions, amount of analgesia, days of stay in hospital, cost of oral care or patient quality of life.
0 studies
No studies found
Presence/absence of HSV oral lesions · Patients being treated for cancer (predominantly haematological malignancies)
Prophylactic aciclovir (oral or intravenous) led to lower presence/absence of HSV oral lesions compared with placebo; GRADE not reported.
1 finding from 1 review
Length of hospital stay · Patients being treated for cancer (predominantly haematological malignancies)
The review found no eligible studies for this question.
1 finding from 1 review
Patient quality of life · Patients being treated for cancer with established oral HSV infection (bone marrow transplant recipients / immunocompromised)
The review found no eligible studies for this question.
1 finding from 1 review
For the treatment comparison (aciclovir versus placebo), no data were available for recurrence of lesions, amount of analgesia, days of stay in hospital, cost of oral care or patient quality of life.
0 studies
No studies found
Recurrence of lesions · Patients being treated for cancer (predominantly haematological malignancies)
The review found no eligible studies for this question.
1 finding from 1 review
Adverse effects · Patients being treated for cancer with established oral HSV infection (bone marrow transplant recipients / immunocompromised)
1 finding from 1 review
Cost of oral care · Patients being treated for cancer with established oral HSV infection (bone marrow transplant recipients / immunocompromised)
The review found no eligible studies for this question.
1 finding from 1 review
For the treatment comparison (aciclovir versus placebo), no data were available for recurrence of lesions, amount of analgesia, days of stay in hospital, cost of oral care or patient quality of life.
0 studies
No studies found
Viral isolates · Patients being treated for cancer (leukaemia)
Prophylactic prostaglandin E (oral) led to higher viral isolates compared with placebo; GRADE not reported.
1 finding from 1 review
Adverse effects · Patients being treated for cancer (predominantly haematological malignancies)
1 finding from 1 review